

CONTACT
040 6761 1600 / 6761 1700
neuland@neulandlabs.com
neulandlabs.com

October 24, 2026

To

BSE Limited

Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai – 400 001

The National Stock Exchange of India Ltd

Exchange Plaza,
Bandra Kurla Complex
Bandra (E), Mumbai – 400 001

Scrip Code: 524558

Scrip Code: NEULANDLAB; Series: EQ

Dear Sir/Madam,

Sub: Newspaper advertisement regarding Special Window for transfer and dematerialization of physical shares

Pursuant to Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015, please find enclosed copies of newspaper advertisement informing about the opening of a Special Window for transfer and dematerialization of physical shares, in accordance with SEBI Circular No. HO/38/13/11(2)2026-MIRSD-PoD/I/3750/2026 dated January 30,2026, as published in Financial Express and Nava Telangana on October 24, 2026.

This is for your information and records.

Thanking You,

Yours sincerely,

For **Neuland Laboratories Limited**

SARADA

BHAMIDIPATI

Digitally signed by
SARADA BHAMIDIPATI
Date: 2026.10.24
18:02:49 +05'30'

Sarada Bhamidipati

Company Secretary

Encl: As above



FDC LIMITED
(CIN: L24239MH1940PLC003176)
Registered Office: FDC House, C-11 & 12, Dalia Industrial Estate, Oshiwara Village, Off New Link Road, Andheri - West, Mumbai – 400 053, Maharashtra, INDIA
Tel : 022-69107100 Email: investors@fdcindia.com Website: www.fdcindia.com

PUBLIC NOTICE
(Under Paragraph 21(2) of Drugs (Prices Control) Order, 2013)
FDC Limited, FDC House, C-11 & 12, Dalia Industrial Estate, Oshiwara Village, Off New Link Road, Andheri (West), Mumbai – 400053, hereby gives notice of its intention to discontinue the manufacture and marketing of the following scheduled formulations after six months from the date of publication of this notice:

S. No.	Product	Composition
1.	Ten DC 20 mg Tablet	Teneligliptin 20 mg
2.	Methron 40 Injection	Methylprednisolone 40 mg

Upon discontinuation, these medicines may not be available in the market. Patients currently using these medicines are advised to consult their doctor regarding suitable alternatives. Doctors and medical professionals may also kindly take note of the same.

Date: 23.10.2026
Place: Mumbai

For FDC Limited
Authorised Signatory



E-Auction
3rd Nov 2026
Sale of
Salvage Materials
(Cement Segment with Steel)
Location : Mumbai
Contact :
Shyamal 8116427552
shyamalj@synise.com
www.synise.com

"IMPORTANT"
Whilst care is taken prior to acceptance of advertising copy, it is not possible to verify its contents. The Indian Express (P) Limited cannot be held responsible for such contents, nor for any loss or damage incurred as a result of transactions with companies, associations or individuals advertising in its newspapers or Publications. We therefore recommend that readers make necessary inquiries before sending any money or entering into any agreements with advertisers or otherwise acting on an advertisement in any manner whatsoever.



IT Quality Assurance Centre of Excellence Dept., State Bank of India,
Global IT-Centre, Sec-11, CBD Belapur, Navi Mumbai-400 614
E-mail: dgm.it.qacoe@sbi.co.in; Website: https://sbi.bank.in

CORRIGENDUM NOTICE
RFP NO. SBI/GITC/IT-Quality Assurance CoE/2026-27/1492
DATED: 18.09.2026
The RFP stands cancelled due to changes in requirements.
IT Quality Assurance Centre of Excellence Dept.



NEULAND LABORATORIES LIMITED
(CIN : L85195TG1984PLC004393)
Registered office: 11th Floor (5th Office Level), Phoenix IVY Building,
Plot No. 573A-III, Road No. 82, Jubilee Hills, Hyderabad, 500033, Telangana, India.
ir@neulandlabs.com, www.neulandlabs.com. Tel: 040 6761 1600,

NOTICE TO SHAREHOLDERS
SPECIAL WINDOW FOR TRANSFER AND DEMATERIALIZATION OF PHYSICAL SHARES
Notice is hereby given that SEBI vide its Circular No. HO/38/13/11(2)2026-MIRSD-PoD/V/3750/2026 dated January 30, 2026, has opened another special window for transfer and dematerialization ("demat") of physical securities which were sold/purchased prior to April 01, 2019. The special window shall be open for a period of one year from February 05, 2026 to February 04, 2027.
The transfer requests, which were submitted earlier and were rejected/returned/not attended to, due to deficiency in the documents/process/or otherwise, are required to be re-lodged during the period from February 05, 2026 to February 04, 2027 with our Registrar and Transfer Agent (RTA) viz. KFin Technologies Limited at their office at Selenium Building, Tower-B, Plot No. 31 & 32, Financial District Nanakramguda, Serilingampally, Hyderabad, Rangareddy, Telangana, India – 500 032, or Email: einward.ris@kfintech.com, RTA Website: https://ris.kfintech.com
All securities transferred under this special window shall be mandatorily credited to the transferee only in demat mode and shall be under lock-in for a period of one year from the date of registration of transfer. Such securities shall not be transferred /lien-marked/ pledged during the said lock-in period.
The transferee shall be mandatorily required to submit all the documents, as prescribed under the aforesaid SEBI circular. Cases involving disputes between transferor and transferee and securities that have been transferred to Investor Education and Protection Fund (IEPF) will not be considered under this special window.
By Order of the Board
For Neuland Laboratories Limited
SD/-
Sarada Bhamidipati
Company Secretary
Place: Hyderabad
Date: October 23, 2026

NOTICE FOR ISSUE OF DUPLICATE SHARE CERTIFICATES
Notice is hereby given that share certificates relating to **5,23,200 equity shares of ₹10 each of Kit Commercial Private Limited and 17,80,000 equity shares of ₹10 each of Olympia Credits & Mercantile Private Limited**, both having their registered office at 4/1, Middleton Street, Sikkim House, 4th Floor, Kolkata – 700071, standing in the name of **MAHANT VANUJA PRIVATE LIMITED**, have been lost and applications for issue of duplicate/consolidated share certificates have been made. The details are as follows:

Company	Certificate Nos.	Distinctive Nos.	Certificate Nos.	Distinctive Nos.
Kit Commercial Private Limited	1-2	1-200	49	802201-812200
	25	490201-491200	51-54	822201-862200
	28	546201-556200	56-58	870201-922200
	33	606201-616200	60-68	976201-1036200
	35-38	626201-656200	87-99	1122201-1186200
	40-43	676201-722200	104-105	1206201-1216200
Olympia Credits & Mercantile Private Limited	45	742201-762200	110-141	1236201-1396200
	47	782201-792200		
	2-3	1-400000	16	2700001-2760000
	8-13	1200001-2400000	19-20	2880001-3000000

Objections, if any, should be made within 15 days from the date of this publication to the Company's Registrar & Share Transfer Agent – Niche Technologies Pvt. Ltd., D-511 Bagree Market, 5th Floor, 71 B. R. B. Basu Road, Kolkata – 700001. The public are cautioned against dealing in any way with these shares.

MAHANT VANUJA PRIVATE LIMITED
CIN: U51109WB1995PTC071398
Date: 23.10.2026



BSE LIMITED
25th Floor, P.J. Towers, Dalal Street, Mumbai – 400 001
CIN No: L67120MH2005PLC155188

PUBLIC NOTICE
The Exchange has initiated the process of compulsory delisting of companies which have been suspended for a period of more than 6 months for non-compliance with critical regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 / clauses of the erstwhile Listing Agreement or suspended for other reasons and have not completed the formalities for revocation of suspension within the stipulated timelines.
As part of the process, Exchange has issued a letter dated October 21, 2026 at their last known address as per Exchange as well as MCA records (where different), informing the said companies to avail the opportunity of personal hearing before the Delisting Committee.
The details of such companies and addresses of their registered offices are as given below:

Sr. No.	Scrip Code	Company Name	Address as per Exchange records
1	526737	Corporate Courier and Cargo Ltd	19, Parsi Panchayat Road, Andheri East, Mumbai - 400068, Maharashtra
2	532745	Inditrade Capital Ltd	Second Floor, MES Building, Kaloor, Ernakulam, Kochi - 682017, Kerala
3	506867	Master Chemicals Ltd	25-28, Plot No. 209, Atlanta Building, Jamnalal Bajaj Marg, Nariman Point, Mumbai - 400021, Maharashtra
4	543579	Naturo Indiabull Ltd	51, 1 st Floor, Lohiya Colony, 200 Ft. Bye Pass, Vaishali Nagar, Jaipur - 302021, Rajasthan
5	526773	Pressure Sensitive Systems India Ltd	441 Block-C I-1 TPS-14 Sumel-II, Indian Textile Plaza, Shahibaug, Ahmedabad - 380004, Gujarat
6	515127	Ramasigns Industries Ltd	Gala No.62,64,65 Ground Floor, Building No.5, New Ashirwad Industrial Premises Co. op Society Limited, Ram Mandir Road, Goregaon (West), Mumbai - 400104, Maharashtra
7	543274	Suumaya Corporation Ltd	19B, 2 nd Floor, B. B. Ganguly Street, Kolkata-700012, West Bengal
8	532035	Unistar Multimedia Ltd	273, Satra Plaza, Sector 19D, Palm Beach Road, Vashi, Thane - 400705, Maharashtra
9	531444	Vardhman Concrete Ltd	Survey No 35 / 10, Lohop Village, District Raigad, Khalapur - 410220, Maharashtra

Further, in respect of aforementioned companies, the Exchange had also sent emails on registered email ids of companies as available in Exchange records. Also, emails enclosing copy of the said letter were sent to promoters of the companies as per details available on Exchange records.
In light of the aforesaid, this notice is being issued by the Exchange to inform that a **last and final opportunity** is being granted to companies to inform whether they want to avail of a **personal hearing** before the Delisting Committee of the Exchange in its meeting scheduled on **November 03, 2026**. Please note that if no confirmation is received from the Company strictly within the stipulated timelines and prescribed mode given below, it would be assumed that the Company has waived the opportunity of being heard and Delisting Committee shall be constrained to decide the matter, on an ex-parte basis. The Exchange would proceed with the process of compulsory delisting as per the provisions of SEBI (Delisting of Equity Shares) Regulations.
The aforementioned companies may address a communication at the specified email id: **bse.delistscn@bseindia.com** by **October 26, 2026**.
If the companies included in this notice, fail to respond within the mandated timeline in the prescribed mode, it will be presumed that these companies have waived their requirement of personal hearing and the **Exchange shall proceed with the procedure for compulsory delisting of the companies under the provisions of SEBI (Delisting of equity shares) Regulations**.
For and on behalf of BSE Ltd.
October 24, 2026



GENNOVA BIOPHARMACEUTICALS LTD
CIN U24231PN2001PLC016253
Regd. Office: Plot No. P-1 & P-2, IT-BT Park, Phase II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India.
Phone No.: +91 20 3507 0105

Public Notice
This is to notify to all trade stockiest/wholesalers/retailer/hospital/consumer and public at large that M/S Gennova Biopharmaceuticals Ltd has notified reduction in MRP's of various formulations in compliance with notification for Trade Margin Rationalization of Non-Scheduled Anti-Cancer Drugs under Paragraph 19 of DPCO, 2013. Vide S.O. 5690 (E) dated 17th October, 2026. As per legal requirement, all trade channels are requested to pass on the benefit of the reduced prices to consumers and ensure billing at the revised MRP as per the current price list or the printed MRP on the pack, whichever is lower.
Sr. No. Name of Product Pack MRP effective from 9th November 2026
1 GENNODAB INJECTION PFS 7,001.28
2 HAMSYL INJECTION VIAL 50,668.60
3 HAMSYL JUNIOR INJECTION VIAL 22,971.57
4 PEGEX INJECTION PFS 1,527.78
For more details, please scan the QR code



For Gennova Biopharmaceuticals Ltd.
SD/-
Authorised Signatory



EMCURE PHARMACEUTICALS LIMITED
CIN L24231PN1981PLC024251
Regd. Office: Plot No. P-1 & P-2, IT-BT Park, Phase II, M.I.D.C., Hinjawadi, Pune - 411 057, Maharashtra, India.
Phone No.: +91 20 3507 0033

Public Notice
This is to notify to all trade stockiest/wholesalers/retailer/hospital/consumer and public at large that M/S Emcure Pharmaceuticals Ltd has notified reduction in MRP's of various formulations in compliance with notification for Trade Margin Rationalization of Non-Scheduled Anti-Cancer Drugs under Paragraph 19 of DPCO, 2013. Vide S.O. 5690 (E) dated 17th October, 2026. As per legal requirement, all trade channels are requested to pass on the benefit of the reduced prices to consumers and ensure billing at the revised MRP as per the current price list or the printed MRP on the pack, whichever is lower.
Sr. No. Name of Product Pack MRP effective from 9th November 2026
1 BEVAREST 100 INJECTION VIAL 3,843.84
2 BEVAREST 400 INJECTION VIAL 12,596.14
3 BRCAONE 100 MG. TABLET 60 T 12,038.37
4 BRCAONE 150 MG. TABLET 60 T 11,573.68
5 CONSIUM 100 INJECTION VIAL 5,396.73
6 DENMAB INJECTION PFS 6,697.50
7 ELINAL TABLET 10 T 78.63
8 EMBREMA INJECTION VIAL 9,880.99
9 EMMDARA 50 MG. INJECTION VIAL 9,449.79
10 EMRAXI 0.25 MG. TABLET 10 T 531.07
11 EMRAXI 0.50 MG. TABLET 10 T 832.11
12 EMTREO INJECTION VIAL 21,902.70
13 ENZUTA CAPSULE 28 C 4,157.65
14 FULVIRA 1 X 5 ML. INJECTION PFS 3,900.41
15 FULVIRA 2 X 5 ML. INJECTION PFS 9,806.64
16 PEMCURE 100 INJECTION VIAL 466.54
17 PEMCURE 500 INJECTION VIAL 1,250.01
18 RUPARIB 200 TABLET 60 T 29,070.28
19 RUPARIB 300 TABLET 60 T 29,945.46
20 TEPAPRO 100 INJECTION VIAL 39,109.93
21 TEPAPRO INJECTION VIAL 8,868.63
For more details, please scan the QR code



For Emcure Pharmaceuticals Ltd.
SD/-
Authorised Signatory



JINDAL STEEL LIMITED
(Formerly known as Jindal Steel & Power Limited)
(CIN: L27105HR1979PLC009913)
Regd. Office: O. P. Jindal Marg, Hisar -125005 (Haryana)
Corporate Office: Jindal Centre, 12 Bhikaiji Cama Place, New Delhi-110066
Phone: +91 11 41462000 | Fax: +91 11 26161271 | Email: contactus@jindalsteel.in
Website: www.jindalsteel.in



DCB BANK LIMITED
CIN No.: L99999MH1995PLC089008
Regd. Office: 601 & 602, 6th Floor, Tower A, Peninsula Business Park, Senapati Bapat Marg, Lower Parel, Mumbai - 400013
EXTRACT FROM UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026
(₹ in crore)

DCB BANK

Sr. No.	Particulars	Quarter ended			Half Year Ended	
		30.09.2026 (Unaudited)	30.06.2026 (Unaudited)	30.09.2025 (Unaudited)	30.09.2026 (Audited)	30.09.2025 (Audited)
1	Total income from operations	2,299.75	2,180.64	2,008.84	4,480.39	4,058.53
2	Net Profit / (Loss) for the period (before tax, exceptional and/or extraordinary items)	318.05	286.97	243.39	605.02	455.14
3	Net Profit / (Loss) for the period before tax (after exceptional and/or extraordinary items)	318.05	286.97	243.39	605.02	455.14
4	Net Profit / (Loss) for the period after tax (after exceptional and / or extraordinary items)	236.39	213.20	183.91	449.59	341.17
5	Equity Share Capital (Face value ₹ 10/-)	322.19	322.08	315.16	322.19	315.16
6	Reserves (excluding Revaluation Reserve)	5,824.24*	5,824.24*	5,090.18**	5,824.24*	5,090.18**
7	Earnings Per Share (EPS) ₹ (before/after extraordinary items) (facevalue of ₹10 each) not annualised					
	(i) Basic (₹)	7.34	6.62	5.84	13.96	10.85
	(ii) Diluted (₹)	7.29	6.58	5.81	13.86	10.78
8	Total Comprehensive Income for the period [comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	Refer Note 2	Refer Note 2	Refer Note 2	Refer Note 2	Refer Note 2
9	Net Worth	6,387.53	6,216.54	5,557.21	6,387.53	5,557.21
10	Outstanding Redeemable Preference Shares	-	-	-	-	-
11	Capital Redemption Reserve	-	-	-	-	-
12	Securities Premium Account	1,472.28	1,471.24	1,387.23	1,472.28	1,387.23
13	Outstanding Debts	5,750.56	5,021.32	5,928.85	5,750.56	5,928.85
14	Total Debt to Total Assets	6.21%	5.66%	7.52%	6.21%	7.52%
15	Debt-Equity Ratio	0.40	0.44	0.29	0.40	0.29

* As on 31 March 2026
** As on 31 March 2025
Notes
1. The above is an extract of the detailed format of Financial Results filed with the Stock Exchanges under Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. The full format of the Financial Results is available on the Stock Exchange and the Bank's URLs as below, which can also be accessed by scanning the QR code provided:
a. BSE: https://www.bseindia.com/xml-data/corpfiling/AttachLive/2dc5423d-1096-4dc5-842a-6bf4b04f1ed9.pdf
b. NSE: https://search.nseindia.com/corporate/Priyeshjain_23102026153153_BSENSEOutcomeOFBoardMeeting_23102026.pdf
c. DCB Bank's website: https://www.dcb.bank.in/about-us/investor-relations#corporate_governance
2. Information relating to Total Comprehensive Income and Other Comprehensive Income is not furnished as Ind AS is not yet made applicable to banks.
3. Outstanding Debts represents Total Borrowings of the Bank.
Place: Mumbai
Date: October 23, 2026
For and on behalf of the Board of Directors
Praveen Kutty
Managing Director & CEO

REGULATION 47 OF SEBI (LODR) REGULATIONS, 2015
EXTRACT OF CONSOLIDATED UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED ON SEPTEMBER 30, 2026
(Rs. in crores except for Shares and EPS)

S. No.	Particulars	Quarter ended on 30th September, 2026	Quarter ended on 30th June, 2026	Quarter ended on 30th September, 2025	Half Year ended on 30th September, 2026	Half Year ended on 30th September, 2025	Financial Year ended on 31st March, 2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Total Income from Operations (net)	16,703.54	15,501.32	11,707.82	32,204.86	24,032.70	53,553.14
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary Items)	1,083.56	1,204.58	982.25	2,288.14	3,000.13	5,284.53
3	Net Profit / (Loss) for the period before tax (after Exceptional Items)	1,083.56	1,204.58	982.25	2,288.14	3,000.13	4,413.15
4	Net Profit / (Loss) for the period after tax (after Exceptional Items)	770.64	843.80	635.08	1,614.44	2,131.05	3,360.87
5	Total Comprehensive Income for the period [Comprising Profits / (Loss) for the period (after tax) and other Comprehensive Income (after tax)]	675.87	943.66	505.77	1,619.53	2,055.38	3,335.95
6	Paid up Equity Share Capital (Face Value of Re. 1/- each)	101.80	101.78	101.75	101.80	101.75	101.75
7	Other equity (excluding Revaluation Reserve)	-	-	-	-	-	50,797.16
8	Earnings Per Share (Face Value of Re. 1/- each) (for continuing and discontinued operations)-						
	Basic:	7.61	8.30	6.28	15.91	20.99	33.12
	Diluted:	7.61	8.30	6.28	15.91	20.99	33.12

Notes:
1. The above is an extract of the detailed format of Un-Audited Financial Results for the quarter and six months ended on September 30, 2026, filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Un-Audited Financial Results for the quarter and six months ended on September 30, 2026, is available on the website of Stock Exchange(s) at www.bseindia.com / www.nseindia.com as well as on the Company's Website at www.jindalsteel.in and can also be accessed by scanning the following Quick response Code.
2. These Un-Audited Financial Results have been reviewed by the Audit Committee in its meeting held on October 23, 2026 and were approved by the Board of Directors in their meeting held on October 23, 2026.

KEY NUMBERS OF FINANCIAL RESULTS ON STANDALONE BASIS
(Rs. in crores)

S. No.	Particulars	Quarter ended on 30th September, 2026	Quarter ended on 30th June, 2026	Quarter ended on 30th September, 2025	Half Year ended on 30th September, 2026	Half Year ended on 30th September, 2025	Financial Year ended on 31st March, 2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Turnover	15,289.22	15,291.77	12,119.03	30,580.99	24,555.30	54,320.20
2	Profit/(Loss) before Tax	1,170.35	1,473.59	1,244.04	2,643.94	3,440.61	4,139.97
3	Profit / (Loss) after Tax	860.65	1,085.97	920.67	1,946.62	2,544.57	3,073.62

By Order of the Board
Vidya Rattan Sharma
Managing Director

Place: New Delhi
Dated: 23rd October, 2026



